07:47 AM EDT, 10/09/2025 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Thursday it has expanded its FLAMINGO-01 clinical trial to Austria.

The company said it will collaborate with principal investigators at the Ordensklinikum Linz hospital in Upper Austria.

FLAMINGO-01 is a phase 3 clinical trial designed to evaluate the safety and efficacy of GLSI-100, a drug candidate intended to prevent breast cancer recurrences, the company said.

Countries involved in the clinical trial include France, Spain, Germany, the US, and others, it said.

Greenwich LifeSciences ( GLSI ) shares were up over 1% in recent Thursday premarket activity.